SCHEDULE 13G: Deep Track Capital Discloses 5.07% Stake in Oruka Therapeutics

Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, has disclosed a beneficial ownership of 5.07% in Oruka Therapeutics, Inc.'s common stock.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have jointly filed a Schedule 13G, indicating their collective beneficial ownership in Oruka Therapeutics, Inc.
• The reporting group beneficially owns an aggregate of 1,896,780 shares of Oruka Therapeutics, Inc. Common Stock.
• This ownership represents 5.07% of the total outstanding Common Stock of Oruka Therapeutics, Inc.
• The shares are held with shared voting power and shared dispositive power, both amounting to 1,896,780 shares.
• The filing explicitly states that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer, nor in connection with any transaction having such purpose or effect, other than activities solely related to a nomination under Rule 14a-11.
• The percentage of ownership is calculated based on 37,440,510 Common Stock outstanding as of February 28, 2025, as reported in Oruka Therapeutics' 10-K filing on March 6, 2025.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing is a factual disclosure of ownership, which can be viewed positively as a vote of confidence from an institutional investor, but it does not contain performance data or strategic updates from the issuer.

Positives

• The disclosure of a significant stake (over 5%) by an institutional investor like Deep Track Capital can be perceived as a vote of confidence in Oruka Therapeutics, Inc.'s future prospects.

Future Outlook

The document does not contain any forward-looking statements or guidance from Oruka Therapeutics, Inc. or the reporting persons regarding the issuer's future performance.

Industry Context

This filing indicates that a specialized institutional investor, Deep Track Capital, has taken a significant passive stake in Oruka Therapeutics, a biotechnology company. Such investments are common in the biotech sector, where funds often invest in companies with promising pipelines or technologies, signaling potential market interest in the company's long-term prospects.

Stakeholder Impact

• Shareholders: The disclosure of a new significant institutional investor holding over 5% of the common stock may be viewed positively by existing and potential shareholders, potentially increasing investor confidence and market interest in Oruka Therapeutics, Inc.

Next Steps

• The reporting persons will be required to file amendments to this Schedule 13G if there are material changes to their beneficial ownership, such as an increase or decrease of 1% or more.

Key Dates

Keywords

Oruka Therapeutics, Deep Track Capital, Deep Track Biotechnology Master Fund, David Kroin, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Biotechnology, Investment